This includes all‐trans‐retinoic acid (ATRA) targeted therapy for RAR rearranged AML, FLT3 inhibitors for FLT3 mutated subtypes, IDH1/2 inhibitors for IDH mutated groups and hypomethylating agents. This evidence concerns the gene IDH2 and acute myeloid leukemia.